{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:50:44Z","timestamp":1791899444743,"version":"4.3.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Azerbaijani Government Scholarship"},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/X511171\/1"],"award-info":[{"award-number":["BB\/X511171\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/W020033\/1"],"award-info":[{"award-number":["BB\/W020033\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Breast cancer (BCa) is the most frequently diagnosed malignancy in women worldwide, with approximately 70% of cases driven by oestrogen receptor alpha (ER\u03b1). Endocrine therapies aim to suppress ER\u03b1 signalling activity and form the foundation of current therapeutic strategies. However, a substantial proportion of patients either\u00a0fail to respond due to intrinsic resistance or acquire resistance over the course of the treatment. This resistance arises through a complex interplay of factors including crosstalk with other signalling pathways such as Notch. Notch signalling, essential for mammary gland development, is aberrantly activated in breast tumours, where it contributes to cancer stem cell maintenance, epithelial-mesenchymal transition, angiogenesis, and metastasis. Notch receptors exert context- and subtype-specific roles: Notch1 and 4 promote tumour aggressiveness, whereas Notch2 often exhibits tumour-suppressive roles. In ER\u03b1-positive BCa, ER\u03b1 and Notch signalling cooperate to drive resistance, whereas in ER\u03b1-negative disease, Notch promotes stemness and angiogenesis. While anti-oestrogen therapies effectively inhibit tumour growth, they can paradoxically activate Notch signalling and promote therapeutic resistance. Co-targeting Notch alongside endocrine therapy has been proposed as a strategy to delay the onset of therapeutic resistance. However, clinical development of Notch inhibitors has been limited by toxicity associated with pan-Notch blockade. More selective approaches, such as paralogue-specific antibodies, transcription-complex disruption, rational drug combinations, and advanced delivery platforms, are under active development to overcome these limitations. This review outlines the ER\u03b1-Notch crosstalk in BCa and examines current and emerging strategies for targeting Notch to overcome endocrine resistance and improve clinical outcomes.<\/jats:p>","DOI":"10.1007\/s10555-026-10331-4","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:28:37Z","timestamp":1774603717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of Notch signalling and its crosstalk with oestrogen receptor signalling in breast cancer"],"prefix":"10.1007","volume":"45","author":[{"given":"Aygun","family":"Azadova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orkhan","family":"Isayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg N.","family":"Brooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"3","key":"10331_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"9","key":"10331_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2023.E20224","volume":"9","author":"K Al-Shami","year":"2023","unstructured":"Al-Shami, K., Awadi, S., Khamees, A., Alsheikh, A. M., Al-Sharif, S., Ala\u2019 Bereshy, R., & Al Zoubi, M. S. (2023). Estrogens and the risk of breast cancer: A narrative review of literature. Heliyon, 9(9), Article e20224. https:\/\/doi.org\/10.1016\/J.HELIYON.2023.E20224","journal-title":"Heliyon"},{"issue":"6","key":"10331_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/CCO.0000000000001085","volume":"36","author":"L Ascione","year":"2024","unstructured":"Ascione, L., Castellano, G., Curigliano, G., & Zagami, P. (2024). Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: Challenges and future perspectives. Current Opinion in Oncology, 36(6), 465\u2013473. https:\/\/doi.org\/10.1097\/CCO.0000000000001085","journal-title":"Current Opinion in Oncology"},{"issue":"7","key":"10331_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS11071028","volume":"11","author":"D Rodriguez","year":"2019","unstructured":"Rodriguez, D., Ramkairsingh, M., Lin, X., Kapoor, A., Major, P., & Tang, D. (2019). The central contributions of breast cancer stem cells in developing resistance to endocrine therapy in estrogen receptor (ER)-positive breast cancer. Cancers, 11(7), Article 1028. https:\/\/doi.org\/10.3390\/CANCERS11071028","journal-title":"Cancers"},{"issue":"10","key":"10331_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/S41568-023-00604-3","volume":"23","author":"M Will","year":"2023","unstructured":"Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023). Therapeutic resistance to anti-oestrogen therapy in breast cancer. Nature Reviews Cancer, 23(10), 673\u2013685. https:\/\/doi.org\/10.1038\/S41568-023-00604-3","journal-title":"Nature Reviews Cancer"},{"issue":"10","key":"10331_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS9102204","volume":"9","author":"M BeLow","year":"2020","unstructured":"BeLow, M., & Osipo, C. (2020). Notch signaling in breast cancer: A role in drug resistance. Cells, 9(10), Article 2204. https:\/\/doi.org\/10.3390\/CELLS9102204","journal-title":"Cells"},{"key":"10331_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2021.692173","volume":"9","author":"A Edwards","year":"2021","unstructured":"Edwards, A., & Brennan, K. (2021). Notch signalling in breast development and cancer. Frontiers in Cell and Developmental Biology, 9, Article 692173. https:\/\/doi.org\/10.3389\/FCELL.2021.692173","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"1","key":"10331_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01825-8","volume":"4","author":"K Pappas","year":"2021","unstructured":"Pappas, K., Martin, T. C., Wolfe, A. L., Nguyen, C. B., Su, T., Jin, J., & Parsons, R. (2021). NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Communications Biology, 4(1), Article 312. https:\/\/doi.org\/10.1038\/s42003-021-01825-8","journal-title":"Communications Biology"},{"issue":"33","key":"10331_CR9","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1038\/s41388-018-0251-y","volume":"37","author":"A Baker","year":"2018","unstructured":"Baker, A., Wyatt, D., Bocchetta, M., Li, J., Filipovic, A., Green, A., & Osipo, C. (2018). Notch-1-PTEN-ERK1\/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene, 37(33), 4489\u20134504. https:\/\/doi.org\/10.1038\/s41388-018-0251-y","journal-title":"Oncogene"},{"issue":"11","key":"10331_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS23116296","volume":"23","author":"A Chimento","year":"2022","unstructured":"Chimento, A., D\u2019amico, M., Pezzi, V., & De Amicis, F. (2022). Notch signaling in breast tumor microenvironment as mediator of drug resistance. International Journal of Molecular Sciences, 23(11), Article 6296. https:\/\/doi.org\/10.3390\/IJMS23116296","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10331_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., & Li, L. (2024). Notch signaling pathway in cancer: From mechanistic insights to targeted therapies. Signal Transduction and Targeted Therapy, 9(1), Article 128. https:\/\/doi.org\/10.1038\/s41392-024-01828-x","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10331_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEO.2024.101041","volume":"57","author":"K Yao","year":"2024","unstructured":"Yao, K., Zhan, X. Y., Feng, M., Yang, K. F., Zhou, M. S., & Jia, H. (2024). Furin, ADAM, and \u03b3-secretase: Core regulatory targets in the Notch pathway and the therapeutic potential for breast cancer. Neoplasia (New York, N.Y.), 57, Article 101041. https:\/\/doi.org\/10.1016\/J.NEO.2024.101041","journal-title":"Neoplasia (New York, N.Y.)"},{"issue":"1","key":"10331_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1210\/ENDREV\/BNAC017","volume":"44","author":"B Chakraborty","year":"2023","unstructured":"Chakraborty, B., Byemerwa, J., Krebs, T., Lim, F., Chang, C. Y., & McDonnell, D. P. (2023). Estrogen receptor signaling in the immune system. Endocrine Reviews, 44(1), 117\u2013141. https:\/\/doi.org\/10.1210\/ENDREV\/BNAC017","journal-title":"Endocrine Reviews"},{"key":"10331_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","volume":"116","author":"N Fuentes","year":"2019","unstructured":"Fuentes, N., & Silveyra, P. (2019). Estrogen receptor signaling mechanisms. Advances in Protein Chemistry and Structural Biology, 116, 135\u2013170. https:\/\/doi.org\/10.1016\/bs.apcsb.2019.01.001","journal-title":"Advances in Protein Chemistry and Structural Biology"},{"issue":"2","key":"10331_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2024.13268","volume":"30","author":"M Toumba","year":"2024","unstructured":"Toumba, M., Kythreotis, A., Panayiotou, K., & Skordis, N. (2024). Estrogen receptor signaling and targets: Bones, breasts and brain. Molecular Medicine Reports, 30(2), Article 144. https:\/\/doi.org\/10.3892\/mmr.2024.13268","journal-title":"Molecular Medicine Reports"},{"key":"10331_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2022.839005","volume":"13","author":"P Chen","year":"2022","unstructured":"Chen, P., Li, B., & Ou-Yang, L. (2022). Role of estrogen receptors in health and disease. Frontiers in Endocrinology, 13, Article 839005. https:\/\/doi.org\/10.3389\/FENDO.2022.839005","journal-title":"Frontiers in Endocrinology"},{"issue":"1","key":"10331_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/S10911-020-09446-3","volume":"25","author":"KA Dunphy","year":"2020","unstructured":"Dunphy, K. A., Black, A. L., Roberts, A. L., Sharma, A., Li, Z., Suresh, S., Browne, E. P., Arcaro, K. F., Ser-Dolansky, J., Bigelow, C., Troester, M. A., Schneider, S. S., Makari-Judson, G., Crisi, G. M., & Jerry, D. J. (2020). Inter-individual variation in response to estrogen in human breast explants. Journal of Mammary Gland Biology and Neoplasia, 25(1), 51\u201368. https:\/\/doi.org\/10.1007\/S10911-020-09446-3","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"10331_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.916804","volume":"12","author":"Z Gong","year":"2022","unstructured":"Gong, Z., Yang, S., Wei, M., Vlantis, A. C., Chan, J. Y. K., van Hasselt, C. A., Li, D., Zeng, X., Xue, L., Tong, M. C. F., & Chen, G. G. (2022). The isoforms of estrogen receptor alpha and beta in thyroid cancer. Frontiers in Oncology, 12, Article 916804. https:\/\/doi.org\/10.3389\/FONC.2022.916804","journal-title":"Frontiers in Oncology"},{"key":"10331_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/J.MCE.2025.112588","volume":"607","author":"JL Pederick","year":"2025","unstructured":"Pederick, J. L., & Bruning, J. B. (2025). Structural comparison of androstenediol recognition by the human estrogen receptor ligand binding domains. Molecular and Cellular Endocrinology, 607, Article 112588. https:\/\/doi.org\/10.1016\/J.MCE.2025.112588","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10331_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/FENDO.2021.599586","volume":"12","author":"EB Belachew","year":"2021","unstructured":"Belachew, E. B., & Sewasew, D. T. (2021). Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer. Frontiers in Endocrinology, 12, Article 599586. https:\/\/doi.org\/10.3389\/FENDO.2021.599586","journal-title":"Frontiers in Endocrinology"},{"issue":"19","key":"10331_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15194689","volume":"15","author":"P Miziak","year":"2023","unstructured":"Miziak, P., Baran, M., B\u0142aszczak, E., Przybyszewska-Podstawka, A., Ka\u0142afut, J., Smok-Kalwat, J., & Stepulak, A. (2023). Estrogen receptor signaling in breast cancer. Cancers, 15(19), Article 4689. https:\/\/doi.org\/10.3390\/CANCERS15194689","journal-title":"Cancers"},{"issue":"4","key":"10331_CR22","doi-asserted-by":"publisher","DOI":"10.37349\/ETAT.2021.00052","volume":"2","author":"KA Altwegg","year":"2021","unstructured":"Altwegg, K. A., & Vadlamudi, R. K. (2021). Role of estrogen receptor coregulators in endocrine resistant breast cancer. Exploration of Targeted Anti-Tumor Therapy, 2(4), Article 385. https:\/\/doi.org\/10.37349\/ETAT.2021.00052","journal-title":"Exploration of Targeted Anti-Tumor Therapy"},{"issue":"1","key":"10331_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00934-y","volume":"7","author":"B Zhou","year":"2022","unstructured":"Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022). Notch signaling pathway: Architecture, disease, and therapeutics. Signal Transduction and Targeted Therapy, 7(1), Article 95. https:\/\/doi.org\/10.1038\/s41392-022-00934-y","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10331_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2021.649205","volume":"9","author":"F Allen","year":"2021","unstructured":"Allen, F., & Maillard, I. (2021). Therapeutic targeting of notch signaling: From cancer to inflammatory disorders. Frontiers in Cell and Developmental Biology, 9, Article 649205. https:\/\/doi.org\/10.3389\/FCELL.2021.649205","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10331_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-319-89512-3_4","volume":"1066","author":"BM Harvey","year":"2018","unstructured":"Harvey, B. M., & Haltiwanger, R. S. (2018). Regulation of notch function by O-glycosylation. Advances in Experimental Medicine and Biology, 1066, 59\u201378. https:\/\/doi.org\/10.1007\/978-3-319-89512-3_4","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"2","key":"10331_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM12020224","volume":"12","author":"R Revici","year":"2022","unstructured":"Revici, R., Hosseini-Alghaderi, S., Haslam, F., Whiteford, R., & Baron, M. (2022). E3 ubiquitin ligase regulators of Notch receptor endocytosis: From flies to humans. Biomolecules, 12(2), Article 224. https:\/\/doi.org\/10.3390\/BIOM12020224","journal-title":"Biomolecules"},{"issue":"1","key":"10331_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PCBI.1010169","volume":"19","author":"D Chen","year":"2023","unstructured":"Chen, D., Forghany, Z., Liu, X., Wang, H., Merks, R. M. H., & Baker, D. A. (2023). A new model of Notch signalling: Control of Notch receptor cis-inhibition via Notch ligand dimers. PLoS Computational Biology, 19(1), Article e1010169. https:\/\/doi.org\/10.1371\/JOURNAL.PCBI.1010169","journal-title":"PLoS Computational Biology"},{"key":"10331_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.01230","volume":"9","author":"MP Steinbuck","year":"2018","unstructured":"Steinbuck, M. P., & Winandy, S. (2018). A review of Notch processing with new insights into ligand-independent notch signaling in T-cells. Frontiers in Immunology, 9, Article 1230. https:\/\/doi.org\/10.3389\/FIMMU.2018.01230","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10331_CR29","doi-asserted-by":"publisher","DOI":"10.20517\/CDR.2021.53","volume":"4","author":"MV Giuli","year":"2021","unstructured":"Giuli, M. V., Mancusi, A., Giuliani, E., Screpanti, I., & Checquolo, S. (2021). Notch signaling in female cancers: A multifaceted node to overcome drug resistance. Cancer Drug Resistance, 4(4), Article 805. https:\/\/doi.org\/10.20517\/CDR.2021.53","journal-title":"Cancer Drug Resistance"},{"issue":"1","key":"10331_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05666-1","volume":"12","author":"B Swaminathan","year":"2022","unstructured":"Swaminathan, B., Youn, S. W., Naiche, L. A., Du, J., Villa, S. R., Metz, J. B., & Kitajewski, J. K. (2022). Endothelial Notch signaling directly regulates the small GTPase RND1 to facilitate Notch suppression of endothelial migration. Scientific Reports, 12(1), Article 1655. https:\/\/doi.org\/10.1038\/s41598-022-05666-1","journal-title":"Scientific Reports"},{"issue":"1","key":"10331_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-35252-3","volume":"8","author":"ML Nueda","year":"2018","unstructured":"Nueda, M. L., Gonz\u00e1lez-G\u00f3mez, M. J., Rodr\u00edguez-Cano, M. M., Monsalve, E. M., D\u00edaz-Guerra, M. J. M., S\u00e1nchez-Solana, B., & Baladr\u00f3n, V. (2018). DLK proteins modulate NOTCH signaling to influence a brown or white 3T3-L1 adipocyte fate. Scientific Reports, 8(1), Article 16923. https:\/\/doi.org\/10.1038\/s41598-018-35252-3","journal-title":"Scientific Reports"},{"issue":"2","key":"10331_CR32","first-page":"173","volume":"7","author":"J Gao","year":"2017","unstructured":"Gao, J., Long, B., & Wang, Z. (2017). Role of Notch signaling pathway in pancreatic cancer. American Journal of Cancer Research, 7(2), 173\u2013186.","journal-title":"American Journal of Cancer Research"},{"issue":"3","key":"10331_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/S10911-021-09496-1","volume":"26","author":"W Chen","year":"2021","unstructured":"Chen, W., Wei, W., Yu, L., Ye, Z., Huang, F., Zhang, L., & Cai, C. (2021). Mammary development and breast cancer: A notch perspective. Journal of Mammary Gland Biology and Neoplasia, 26(3), 309. https:\/\/doi.org\/10.1007\/S10911-021-09496-1","journal-title":"Journal of Mammary Gland Biology and Neoplasia"},{"key":"10331_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.00924","volume":"11","author":"JW Bai","year":"2020","unstructured":"Bai, J. W., Wei, M., Li, J. W., & Zhang, G. J. (2020). Notch signaling pathway and endocrine resistance in breast cancer. Frontiers in Pharmacology, 11, Article 924. https:\/\/doi.org\/10.3389\/FPHAR.2020.00924","journal-title":"Frontiers in Pharmacology"},{"key":"10331_CR35","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/BCTT.S376873","volume":"14","author":"N Jiang","year":"2022","unstructured":"Jiang, N., Hu, Y., Wang, M., Zhao, Z., & Li, M. (2022). The Notch signaling pathway contributes to angiogenesis and tumor immunity in breast cancer. Breast Cancer, 14, 291\u2013309. https:\/\/doi.org\/10.2147\/BCTT.S376873","journal-title":"Breast Cancer"},{"issue":"1","key":"10331_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8707053","volume":"2019","author":"MV Giuli","year":"2019","unstructured":"Giuli, M. V., Giuliani, E., Screpanti, I., Bellavia, D., & Checquolo, S. (2019). Notch signaling activation as a hallmark for triple-negative breast cancer subtype. Journal of Oncology, 2019(1), Article 8707053. https:\/\/doi.org\/10.1155\/2019\/8707053","journal-title":"Journal of Oncology"},{"issue":"1","key":"10331_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-022-10383-Z","volume":"22","author":"H Yousefi","year":"2022","unstructured":"Yousefi, H., Bahramy, A., Zafari, N., Delavar, M. R., Nguyen, K., Haghi, A., & Babashah, S. (2022). Notch signaling pathway: A comprehensive prognostic and gene expression profile analysis in breast cancer. BMC Cancer, 22(1), Article 1282. https:\/\/doi.org\/10.1186\/S12885-022-10383-Z","journal-title":"BMC Cancer"},{"issue":"4","key":"10331_CR38","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/S12094-019-02156-1","volume":"22","author":"Z Chen","year":"2020","unstructured":"Chen, Z., Yan, X., Li, K., Ling, Y., & Kang, H. (2020). Stromal fibroblast-derived MFAP5 promotes the invasion and migration of breast cancer cells via Notch1\/slug signaling. Clinical and Translational Oncology, 22(4), 522\u2013531. https:\/\/doi.org\/10.1007\/S12094-019-02156-1","journal-title":"Clinical and Translational Oncology"},{"issue":"2","key":"10331_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/CPR.13754","volume":"58","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., Qin, X., Guo, R., Sun, X., Zhao, Z., Guo, H., & Liu, Y. (2025). Notch-1 regulates collective breast cancer cell migration by controlling intercellular junction and cytoskeletal organization. Cell Proliferation, 58(2), Article e13754. https:\/\/doi.org\/10.1111\/CPR.13754","journal-title":"Cell Proliferation"},{"issue":"1","key":"10331_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/S13205-016-0373-2","volume":"6","author":"M Paryan","year":"2016","unstructured":"Paryan, M., Tavakoli, R., Rad, S. M. A. H., Feizi, N., Kamani, F., Mostafavi, E., & Mohammadi-Yeganeh, S. (2016). Over-expression of NOTCH1 as a biomarker for invasive breast ductal carcinoma. 3 Biotech, 6(1), Article 58. https:\/\/doi.org\/10.1007\/S13205-016-0373-2","journal-title":"3 Biotech"},{"issue":"1","key":"10331_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/S10549-024-07444-1","volume":"209","author":"J Engel","year":"2025","unstructured":"Engel, J., Wieder, V., Bauer, M., Kaufhold, S., St\u00fcckrath, K., Wilke, J., & Vetter, M. (2025). Prognostic and predictive impact of NOTCH1 in early breast cancer. Breast Cancer Research and Treatment, 209(1), 27\u201338. https:\/\/doi.org\/10.1007\/S10549-024-07444-1","journal-title":"Breast Cancer Research and Treatment"},{"issue":"3","key":"10331_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/S13402-022-00677-6","volume":"45","author":"D Liu","year":"2022","unstructured":"Liu, D., & Hofman, P. (2022). Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer. Cellular Oncology, 45(3), 463\u2013477. https:\/\/doi.org\/10.1007\/S13402-022-00677-6","journal-title":"Cellular Oncology"},{"key":"10331_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/S00210-025-04082-2","author":"R Gummadi","year":"2025","unstructured":"Gummadi, R., Nori, L. P., Pindiprolu, S. K. S. S., Dasari, N., Ahmad, Z., & Km, M. (2025). Nanomaterials for delivery of drugs and genes to disrupt notch signaling pathway in breast cancer. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology. https:\/\/doi.org\/10.1007\/S00210-025-04082-2","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"issue":"2","key":"10331_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41416-019-0501-y","volume":"121","author":"M Capulli","year":"2019","unstructured":"Capulli, M., Hristova, D., Valbret, Z., Carys, K., Arjan, R., Maurizi, A., & Teti, A. (2019). Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. British Journal of Cancer, 121(2), 157\u2013171. https:\/\/doi.org\/10.1038\/s41416-019-0501-y","journal-title":"British Journal of Cancer"},{"issue":"1","key":"10331_CR45","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/S10549-016-3795-Y","volume":"157","author":"SH Kim","year":"2016","unstructured":"Kim, S. H., Hahm, E. R., Arlotti, J. A., Samanta, S. K., Moura, M. B., Thorne, S. H., & Singh, S. V. (2016). Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Research and Treatment, 157(1), 41\u201354. https:\/\/doi.org\/10.1007\/S10549-016-3795-Y","journal-title":"Breast Cancer Research and Treatment"},{"key":"10331_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221118984","volume":"22","author":"L Wang","year":"2023","unstructured":"Wang, L., Cao, G., Li, W., Chen, X. W., Xiong, S. S., Mu, Y. N., & Cao, Y. W. (2023). Expressions and prognostic values of Notch3 and DLL4 in human breast cancer. Technology in Cancer Research and Treatment, 22, Article 15330338221118984. https:\/\/doi.org\/10.1177\/15330338221118984","journal-title":"Technology in Cancer Research and Treatment"},{"issue":"2","key":"10331_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/J.ARCMED.2017.03.014","volume":"48","author":"S Xue","year":"2017","unstructured":"Xue, S., He, L., Zhang, X., Zhou, J., Li, F., & Wang, X. (2017). Expression of Jagged1\/Notch3 signaling pathway and their relationship with the tumor angiogenesis in TNBC. Archives of Medical Research, 48(2), 169\u2013179. https:\/\/doi.org\/10.1016\/J.ARCMED.2017.03.014","journal-title":"Archives of Medical Research"},{"issue":"1","key":"10331_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1729299","volume":"9","author":"FA Mansour","year":"2020","unstructured":"Mansour, F. A., Al-Mazrou, A., Al-Mohanna, F., Al-Alwan, M., & Ghebeh, H. (2020). PD-L1 is overexpressed on breast cancer stem cells through notch3\/mTOR axis. Oncoimmunology, 9(1), Article 1729299. https:\/\/doi.org\/10.1080\/2162402X.2020.1729299","journal-title":"Oncoimmunology"},{"issue":"2","key":"10331_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/S41419-023-05674-7","volume":"14","author":"S Brahim","year":"2023","unstructured":"Brahim, S., Negulescu, A. M., Geneste, C., Schott, T., Lin, S., Morel, L. O., & Meurette, O. (2023). Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer. Cell Death and Disease, 14(2), Article 171. https:\/\/doi.org\/10.1038\/S41419-023-05674-7","journal-title":"Cell Death and Disease"},{"issue":"6","key":"10331_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/S41419-021-03735-3","volume":"12","author":"YQ Zhang","year":"2021","unstructured":"Zhang, Y. Q., Liang, Y. K., Wu, Y., Chen, M., Chen, W. L., Li, R. H., Zeng, Y.-Z., Huang, W.-H., Wu, J.-D., Zeng, D., Gao, W.-L., Chen, C.-F., Lin, H.-Y., Yang, R.-Q., Zhu, J.-W., Liu, W.-L., Bai, J.-W., Wei, M., Wei, X.-L., & Zhang, G. J. (2021). Notch3 inhibits cell proliferation and tumorigenesis and predicts better prognosis in breast cancer through transactivating PTEN. Cell Death & Disease, 12(6), Article 502. https:\/\/doi.org\/10.1038\/S41419-021-03735-3","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10331_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-023-11746-W","volume":"23","author":"MN Chen","year":"2023","unstructured":"Chen, M. N., Fang, Z. X., Wu, Z., Bai, J. W., Li, R. H., Wen, X. F., Zhang, G.-J., & Liu, J. (2023). Notch3 restricts metastasis of breast cancers through regulation of the JAK\/STAT5A signaling pathway. BMC Cancer, 23(1), 1\u201315. https:\/\/doi.org\/10.1186\/S12885-023-11746-W","journal-title":"BMC Cancer"},{"issue":"1","key":"10331_CR52","doi-asserted-by":"publisher","first-page":"192","DOI":"10.7150\/JCA.89034","volume":"15","author":"WJ Chen","year":"2024","unstructured":"Chen, W. J., Zhong, H. T., Wu, H. T., Hou, Y. Y., Wu, Z., Fang, Z. X., & Liu, J. (2024). NOTCH3 inhibits transcription factor ZEB1 expression and metastasis of breast cancer cells via transcriptionally upregulating miR-223. Journal of Cancer, 15(1), 192\u2013203. https:\/\/doi.org\/10.7150\/JCA.89034","journal-title":"Journal of Cancer"},{"issue":"5","key":"10331_CR53","doi-asserted-by":"publisher","DOI":"10.7150\/THNO.38875","volume":"10","author":"L Zhou","year":"2020","unstructured":"Zhou, L., Wang, D., Sheng, D., Xu, J., Chen, W., Qin, Y., Du, R., Yang, X., He, X., Xie, N., Liu, S., & Zhang, L. (2020). NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics, 10(5), Article 2405. https:\/\/doi.org\/10.7150\/THNO.38875","journal-title":"Theranostics"},{"issue":"6","key":"10331_CR54","doi-asserted-by":"publisher","DOI":"10.3892\/OL.2018.8442","volume":"15","author":"JW Wang","year":"2018","unstructured":"Wang, J. W., Wei, X. L., Dou, X. W., Huang, W. H., Du, C. W., & Zhang, G. J. (2018). The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer. Oncology Letters, 15(6), Article 8749. https:\/\/doi.org\/10.3892\/OL.2018.8442","journal-title":"Oncology Letters"},{"issue":"1","key":"10331_CR55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/1735-5362.363598","volume":"18","author":"A Boustan","year":"2023","unstructured":"Boustan, A., Jahangiri, R., Ghalehno, A. D., Khorsandi, M., Mosaffa, F., & Jamialahmadi, K. (2023). Expression analysis elucidates the roles of Nicastrin, Notch4, and Hes1 in prognosis and endocrine-therapy resistance in ER-positive breast cancer patients. Research in Pharmaceutical Sciences, 18(1), 78\u201388. https:\/\/doi.org\/10.4103\/1735-5362.363598","journal-title":"Research in Pharmaceutical Sciences"},{"key":"10331_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0217002","author":"J Sales-Dias","year":"2019","unstructured":"Sales-Dias, J., Silva, G., Lamy, M., Ferreira, A., & Barbas, A. (2019). The notch ligand DLL1 exerts carcinogenic features in human breast cancer cells. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0217002","journal-title":"PLoS ONE"},{"issue":"1","key":"10331_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20664-5","volume":"12","author":"S Kumar","year":"2021","unstructured":"Kumar, S., Nandi, A., Singh, S., Regulapati, R., Li, N., Tobias, J. W., Siebel, C. W., Blanco, M. A., Klein-Szanto, A. J., Lengner, C., Welm, A. L., Kang, Y., & Chakrabarti, R. (2021). Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-\u03baB survival pathway. Nature Communications, 12(1), Article 432. https:\/\/doi.org\/10.1038\/s41467-020-20664-5","journal-title":"Nature Communications"},{"issue":"12","key":"10331_CR58","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/S41388-018-0562-Z","volume":"38","author":"S Kumar","year":"2019","unstructured":"Kumar, S., Srivastav, R. K., Wilkes, D. W., Ross, T., Kim, S., Kowalski, J., Chatla, S., Zhang, Q., Nayak, A., Guha, M., Fuchs, S. Y., Thomas, C., & Chakrabarti, R. (2019). Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer. Oncogene, 38(12), 2092\u20132107. https:\/\/doi.org\/10.1038\/S41388-018-0562-Z","journal-title":"Oncogene"},{"key":"10331_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANON.2021.101080","author":"C Yuan","year":"2021","unstructured":"Yuan, C., Chang, K., Xu, C., Li, Q., & Du, Z. (2021). High expression of DLL3 is associated with a poor prognosis and immune infiltration in invasive breast cancer patients. Translational Oncology. https:\/\/doi.org\/10.1016\/J.TRANON.2021.101080","journal-title":"Translational Oncology"},{"issue":"12","key":"10331_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/GENES10120961","volume":"10","author":"R Kar","year":"2019","unstructured":"Kar, R., Jha, N. K., Jha, S. K., Sharma, A., Dholpuria, S., Asthana, N., Chaurasiya, K., Singh, V. K., Burgee, S., & Nand, P. (2019). A \u201cNOTCH\u201d deeper into the epithelial-to-mesenchymal transition (EMT) program in breast cancer. Genes, 10(12), Article 961. https:\/\/doi.org\/10.3390\/GENES10120961","journal-title":"Genes"},{"issue":"21\u201322","key":"10331_CR61","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1101\/GAD.342287.120","volume":"34","author":"A Nandi","year":"2020","unstructured":"Nandi, A., & Chakrabarti, R. (2020). The many facets of Notch signaling in breast cancer: Toward overcoming therapeutic resistance. Genes & Development, 34(21\u201322), 1422\u20131438. https:\/\/doi.org\/10.1101\/GAD.342287.120","journal-title":"Genes & Development"},{"issue":"1","key":"10331_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-022-26241-8","volume":"12","author":"X Qiao","year":"2022","unstructured":"Qiao, X., Ma, B., Sun, W., Zhang, N., Liu, Y., Jia, L., & Liu, C. (2022). JAG1 is associated with the prognosis and metastasis in breast cancer. Scientific Reports, 12(1), Article 21986. https:\/\/doi.org\/10.1038\/S41598-022-26241-8","journal-title":"Scientific Reports"},{"issue":"4","key":"10331_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12032-016-0750-Z","volume":"33","author":"H Sun","year":"2016","unstructured":"Sun, H., Li, K., & Shen, S. (2016). A study of the role of Notch1 and JAG1 gene methylation in development of breast cancer. Medical Oncology, 33(4), 1\u201317. https:\/\/doi.org\/10.1007\/S12032-016-0750-Z","journal-title":"Medical Oncology"},{"issue":"18","key":"10331_CR64","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.26355\/EURREV_201809_15936","volume":"22","author":"CY Li","year":"2018","unstructured":"Li, C. Y., Miao, K. L., Chen, Y., Liu, L. Y., Zhao, G. B., Lin, M. H., & Jiang, C. (2018). Jagged2 promotes cancer stem cell properties of triple negative breast cancer cells and paclitaxel resistance via regulating microRNA-200. European Review for Medical and Pharmacological Sciences, 22(18), 6008\u20136014. https:\/\/doi.org\/10.26355\/EURREV_201809_15936","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"25","key":"10331_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/ADVS.202405812","volume":"12","author":"S Sabbioni","year":"2025","unstructured":"Sabbioni, S., Filippone, M. G., Amadori, L., Confalonieri, S., Bonfanti, R., Capoano, S., & Tosoni, D. (2025). The CRL7FBXW8 complex controls the mammary stem cell compartment through regulation of NUMB levels. Advanced Science, 12(25), Article 2405812. https:\/\/doi.org\/10.1002\/ADVS.202405812","journal-title":"Advanced Science"},{"key":"10331_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2498764","volume":"2016","author":"A Acar","year":"2016","unstructured":"Acar, A., Sim\u00f5es, B. M., Clarke, R. B., & Brennan, K. (2016). A role for Notch signalling in breast cancer and endocrine resistance. Stem Cells International, 2016, Article 2498764. https:\/\/doi.org\/10.1155\/2016\/2498764","journal-title":"Stem Cells International"},{"issue":"8","key":"10331_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071440","volume":"8","author":"C Caliceti","year":"2013","unstructured":"Caliceti, C., Aquila, G., Pannella, M., Morelli, M. B., Fortini, C., Pinton, P., & Ferrari, R. (2013). 17\u03b2-estradiol enhances signalling mediated by VEGF-A-Delta-like Ligand 4-Notch1 axis in human endothelial cells. PLoS ONE, 8(8), Article e71440. https:\/\/doi.org\/10.1371\/journal.pone.0071440","journal-title":"PLoS ONE"},{"issue":"7","key":"10331_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS19072011","volume":"19","author":"EM De Francesco","year":"2018","unstructured":"De Francesco, E. M., Maggiolini, M., & Musti, A. M. (2018). Crosstalk between Notch, HIF-1\u03b1 and GPER in breast cancer EMT. International Journal of Molecular Sciences, 19(7), Article 2011. https:\/\/doi.org\/10.3390\/IJMS19072011","journal-title":"International Journal of Molecular Sciences"},{"key":"10331_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2024.1448687","volume":"14","author":"Y Gao","year":"2024","unstructured":"Gao, Y., Yu, Y., Zhang, M., Yu, W., & Kang, L. (2024). Mechanisms of endocrine resistance in hormone receptor-positive breast cancer. Frontiers in Oncology, 14, Article 1448687. https:\/\/doi.org\/10.3389\/FONC.2024.1448687","journal-title":"Frontiers in Oncology"},{"issue":"8","key":"10331_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0069-z","volume":"7","author":"HY Lin","year":"2018","unstructured":"Lin, H. Y., Liang, Y. K., Dou, X. W., Chen, C. F., Wei, X. L., Zeng, D., & Zhang, G. J. (2018). Notch3 inhibits epithelial\u2013mesenchymal transition in breast cancer via a novel mechanism, upregulation of GATA-3 expression. Oncogenesis, 7(8), Article 59. https:\/\/doi.org\/10.1038\/s41389-018-0069-z","journal-title":"Oncogenesis"},{"key":"10331_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00573","volume":"10","author":"MM Haque","year":"2019","unstructured":"Haque, M. M., & Desai, K. V. (2019). Pathways to endocrine therapy resistance in breast cancer. Frontiers in Endocrinology, 10, Article 573. https:\/\/doi.org\/10.3389\/fendo.2019.00573","journal-title":"Frontiers in Endocrinology"},{"issue":"12","key":"10331_CR72","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.celrep.2015.08.050","volume":"12","author":"BM Sim\u00f5es","year":"2015","unstructured":"Sim\u00f5es, B. M., O\u2019Brien, C. S., Eyre, R., Silva, A., Yu, L., Sarmiento-Castro, A., & Clarke, R. B. (2015). Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Reports, 12(12), 1968\u20131977. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.050","journal-title":"Cell Reports"},{"issue":"2","key":"10331_CR73","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/S41573-020-00091-3","volume":"20","author":"S Majumder","year":"2021","unstructured":"Majumder, S., Crabtree, J. S., Golde, T. E., Minter, L. M., Osborne, B. A., & Miele, L. (2021). Targeting Notch in oncology: The path forward. Nature Reviews Drug Discovery, 20(2), 125\u2013144. https:\/\/doi.org\/10.1038\/S41573-020-00091-3","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10331_CR74","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3892\/IJMM.2019.4418","volume":"45","author":"M Katoh","year":"2019","unstructured":"Katoh, M., & Katoh, M. (2019). Precision medicine for human cancers with Notch signaling dysregulation (review). International Journal of Molecular Medicine, 45(2), 279. https:\/\/doi.org\/10.3892\/IJMM.2019.4418","journal-title":"International Journal of Molecular Medicine"},{"key":"10331_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110529","volume":"102","author":"P Sen","year":"2023","unstructured":"Sen, P., Kandasamy, T., & Ghosh, S. S. (2023). Multi-targeting TACE\/ADAM17 and gamma-secretase of notch signalling pathway in TNBC via drug repurposing approach using Lomitapide. Cellular Signalling, 102, Article 110529. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110529","journal-title":"Cellular Signalling"},{"issue":"12","key":"10331_CR76","doi-asserted-by":"publisher","first-page":"15359","DOI":"10.1007\/S13277-016-5418-Y","volume":"37","author":"H Shen","year":"2016","unstructured":"Shen, H., Li, L., Zhou, S., Yu, D., Yang, S., Chen, X., Wang, D., Zhong, S., Zhao, J., & Tang, J. (2016). The role of ADAM17 in tumorigenesis and progression of breast cancer. Tumor Biology, 37(12), 15359\u201315370. https:\/\/doi.org\/10.1007\/S13277-016-5418-Y","journal-title":"Tumor Biology"},{"issue":"3","key":"10331_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/J.HELIYON.2024.E24805","volume":"10","author":"SA Navasatli","year":"2024","unstructured":"Navasatli, S. A., Vahdati, S. N., Arjmand, T. F., Mohammadi far, M., & Behboudi, H. (2024). New insight into the role of the ADAM protease family in breast carcinoma progression. Heliyon, 10(3), Article e24805. https:\/\/doi.org\/10.1016\/J.HELIYON.2024.E24805","journal-title":"Heliyon"},{"key":"10331_CR78","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/J.CANLET.2020.10.013","volume":"496","author":"I Dutta","year":"2021","unstructured":"Dutta, I., Dieters-Castator, D., Papatzimas, J. W., Medina, A., Schueler, J., Derksen, D. J., Lajoie, G., Postovit, L.-M., & Siegers, G. M. (2021). ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to \u03b3\u03b4 T cell immunotherapy. Cancer Letters, 496, 156\u2013168. https:\/\/doi.org\/10.1016\/J.CANLET.2020.10.013","journal-title":"Cancer Letters"},{"issue":"1","key":"10331_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/S10637-014-0166-6","volume":"33","author":"NK Loconte","year":"2015","unstructured":"Loconte, N. K., Razak, A. R. A., Ivy, P., Tevaarwerk, A., Leverence, R., Kolesar, J., & Liu, G. (2015). A multicenter phase 1 study of \u03b3 -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs, 33(1), 169\u2013176. https:\/\/doi.org\/10.1007\/S10637-014-0166-6","journal-title":"Investigational New Drugs"},{"issue":"2","key":"10331_CR80","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/J.CLBC.2021.10.013","volume":"22","author":"JA Means-Powell","year":"2022","unstructured":"Means-Powell, J. A., Mayer, I. A., Ismail-Khan, R., Del Valle, L., Tonetti, D., Abramson, V. G., Sanders, M. S., Lush, R. M., Sorrentino, C., Majumder, S., & Miele, L. (2022). A phase Ib dose escalation trial of RO4929097 (a \u03b3-secretase inhibitor) in combination with exemestane in patients with ER + metastatic breast cancer (MBC). Clinical Breast Cancer, 22(2), 103\u2013114. https:\/\/doi.org\/10.1016\/J.CLBC.2021.10.013","journal-title":"Clinical Breast Cancer"},{"key":"10331_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2018.00575","volume":"8","author":"F Hossain","year":"2018","unstructured":"Hossain, F., Sorrentino, C., Ucar, D. A., Peng, Y., Matossian, M., Wyczechowska, D., Crabtree, J., Zabaleta, J., Morello, S., Del Valle, L., Burow, M., Collins-Burow, B., Pannuti, A., Minter, L. M., Golde, T. E., Osborne, B. A., & Miele, L. (2018). Notch signaling regulates mitochondrial metabolism and NF-\u03baB activity in triple-negative breast cancer cells via IKK\u03b1-dependent non-canonical pathways. Frontiers in Oncology, 8, Article 575. https:\/\/doi.org\/10.3389\/FONC.2018.00575","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10331_CR82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","volume":"21","author":"WA Messersmith","year":"2015","unstructured":"Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., McLachlan, K. R., Kern, K. A., & LoRusso, P. M. (2015). A phase I, dose-finding study in patients with advanced solid malignancies of the oral \u03b3-secretase inhibitor PF-03084014. Clinical Cancer Research, 21(1), 60\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0607","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10331_CR83","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.3390\/CURRONCOL28050312","volume":"28","author":"D Chan","year":"2021","unstructured":"Chan, D., Kaplan, J., Gordon, G., & Desai, J. (2021). Activity of the gamma secretase inhibitor AL101 in desmoid tumors: A case report of 2 adult cases. Current Oncology, 28(5), 3659. https:\/\/doi.org\/10.3390\/CURRONCOL28050312","journal-title":"Current Oncology"},{"issue":"5","key":"10331_CR84","first-page":"4378","volume":"8","author":"ZL Li","year":"2015","unstructured":"Li, Z. L., Chen, C., Yang, Y., Wang, C., Yang, T., Yang, X., & Liu, S. C. (2015). Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells. International Journal of Clinical and Experimental Pathology, 8(5), 4378.","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"2","key":"10331_CR85","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3892\/MMR.2017.8161","volume":"17","author":"XX Lai","year":"2018","unstructured":"Lai, X. X., Li, G., Lin, B., & Yang, H. (2018). Interference of Notch 1 inhibits the proliferation and invasion of breast cancer cells: Involvement of the \u03b2-catenin signaling pathway. Molecular Medicine Reports, 17(2), 2472\u20132478. https:\/\/doi.org\/10.3892\/MMR.2017.8161","journal-title":"Molecular Medicine Reports"},{"issue":"2","key":"10331_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22020849","volume":"22","author":"N Zhang","year":"2021","unstructured":"Zhang, N., Ji, J., Zhou, D., Liu, X., Zhang, X., Liu, Y., & Zhang, Y. (2021). The interaction of the senescent and adjacent breast cancer cells promotes the metastasis of heterogeneous breast cancer cells through Notch signaling. International Journal of Molecular Sciences, 22(2), Article 849. https:\/\/doi.org\/10.3390\/IJMS22020849","journal-title":"International Journal of Molecular Sciences"},{"issue":"44","key":"10331_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/SCIADV.ADO8275","volume":"10","author":"Q Shen","year":"2024","unstructured":"Shen, Q., Murakami, K., Sotov, V., Butler, M., Ohashi, P. S., & Reedijk, M. (2024). Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer. Science Advances, 10(44), Article eado8275. https:\/\/doi.org\/10.1126\/SCIADV.ADO8275","journal-title":"Science Advances"},{"issue":"1","key":"10331_CR88","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1021\/ACSAMI.4C16278","volume":"17","author":"Y Liu","year":"2025","unstructured":"Liu, Y., Zhou, Y., Li, Y., Kang, W., Zhang, Y., Xia, X., & Wang, W. (2025). Notch pathway deactivation sensitizes breast cancer stem cells toward chemotherapy using NIR light-responsive nanoparticles. ACS Applied Materials & Interfaces, 17(1), 430\u2013444. https:\/\/doi.org\/10.1021\/ACSAMI.4C16278","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10331_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/J.CANLET.2019.07.012","volume":"461","author":"BM Krishna","year":"2019","unstructured":"Krishna, B. M., Jana, S., Singhal, J., Horne, D., Awasthi, S., Salgia, R., & Singhal, S. S. (2019). Notch signaling in breast cancer: From pathway analysis to therapy. Cancer Letters, 461, Article 123. https:\/\/doi.org\/10.1016\/J.CANLET.2019.07.012","journal-title":"Cancer Letters"},{"key":"10331_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOPHA.2023.114938","volume":"164","author":"P Pandey","year":"2023","unstructured":"Pandey, P., Khan, F., Choi, M., Singh, S. K., Kang, H. N., Park, M. N., & Kim, B. (2023). Review deciphering potent therapeutic approaches targeting Notch signaling pathway in breast cancer. Biomedicine & Pharmacotherapy, 164, Article 114938. https:\/\/doi.org\/10.1016\/J.BIOPHA.2023.114938","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"10331_CR91","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/S10637-019-00754-Y","volume":"38","author":"LS Rosen","year":"2020","unstructured":"Rosen, L. S., Wesolowski, R., Baffa, R., Liao, K. H., Hua, S. Y., Gibson, B. L., & Tolcher, A. W. (2020). A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody\u2013drug conjugate, in patients with breast cancer and other advanced solid tumors. Investigational New Drugs, 38(1), 120\u2013130. https:\/\/doi.org\/10.1007\/S10637-019-00754-Y","journal-title":"Investigational New Drugs"},{"issue":"1","key":"10331_CR92","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","volume":"22","author":"WK You","year":"2023","unstructured":"You, W. K., Schuetz, T. J., & Lee, S. H. (2023). Targeting the DLL\/Notch signaling pathway in cancer: Challenges and advances in clinical development. Molecular Cancer Therapeutics, 22(1), 3\u201311. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0243","journal-title":"Molecular Cancer Therapeutics"},{"issue":"3","key":"10331_CR93","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/S10637-018-0665-Y","volume":"37","author":"A Jimeno","year":"2019","unstructured":"Jimeno, A., Moore, K. N., Gordon, M., Chugh, R., Diamond, J. R., Aljumaily, R., & Smith, D. C. (2019). A first-in-human phase 1a study of the bispecific anti-DLL4\/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Investigational New Drugs, 37(3), 461\u2013472. https:\/\/doi.org\/10.1007\/S10637-018-0665-Y","journal-title":"Investigational New Drugs"},{"issue":"16","key":"10331_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13164074","volume":"13","author":"G Silva","year":"2021","unstructured":"Silva, G., Sales-Dias, J., Casal, D., Alves, S., Domenici, G., Barreto, C., & Barbas, A. (2021). Development of Dl1.72, a novel anti-DLL1 antibody with anti-tumor efficacy against estrogen receptor-positive breast cancer. Cancers, 13(16), Article 4074. https:\/\/doi.org\/10.3390\/CANCERS13164074","journal-title":"Cancers"},{"issue":"11","key":"10331_CR95","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1535-7163.MCT-18-1176","volume":"18","author":"M Masiero","year":"2019","unstructured":"Masiero, M., Li, D., Whiteman, P., Bentley, C., Greig, J., Hassanali, T., & Banham, A. H. (2019). Development of therapeutic anti-Jagged1 antibodies for cancer therapy. Molecular Cancer Therapeutics, 18(11), 2030\u20132042. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1176","journal-title":"Molecular Cancer Therapeutics"},{"key":"10331_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15153957","author":"M Vigolo","year":"2023","unstructured":"Vigolo, M., Urech, C., Lamy, S., Monticone, G., Zabaleta, J., Hossain, F., & Majumder, S. (2023). The efficacy of CB-103, a first-in-class transcriptional notch inhibitor, in preclinical models of breast cancer. Cancers. https:\/\/doi.org\/10.3390\/CANCERS15153957","journal-title":"Cancers"},{"issue":"3","key":"10331_CR97","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/S00210-020-01988-X","volume":"394","author":"F Nasser","year":"2021","unstructured":"Nasser, F., Moussa, N., Helmy, M. W., & Haroun, M. (2021). Dual targeting of Notch and Wnt\/\u03b2-catenin pathways: Potential approach in triple-negative breast cancer treatment. Naunyn-Schmiedeberg\u2019s Archives of Pharmacology, 394(3), 481\u2013490. https:\/\/doi.org\/10.1007\/S00210-020-01988-X","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"key":"10331_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2023.1150774","volume":"14","author":"U Saran","year":"2023","unstructured":"Saran, U., Chandrasekaran, B., Tyagi, A., Shukla, V., Singh, A., Sharma, A. K., & Damodaran, C. (2023). A small molecule inhibitor of Notch1 modulates stemness and suppresses breast cancer cell growth. Frontiers in Pharmacology, 14, Article 1150774. https:\/\/doi.org\/10.3389\/FPHAR.2023.1150774","journal-title":"Frontiers in Pharmacology"},{"key":"10331_CR99","doi-asserted-by":"publisher","DOI":"10.1186\/S12935-023-02958-Y","author":"I Ahmad","year":"2023","unstructured":"Ahmad, I., Pal, S., Singh, R., Ahmad, K., Dey, N., Srivastava, A., & Siddiqui, S. (2023). Antimicrobial peptide moricin induces ROS mediated caspase-dependent apoptosis in human triple-negative breast cancer via suppression of notch pathway. Cancer Cell International. https:\/\/doi.org\/10.1186\/S12935-023-02958-Y","journal-title":"Cancer Cell International"},{"issue":"5","key":"10331_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/BIOMEDICINES9050482","volume":"9","author":"P Ramamoorthy","year":"2021","unstructured":"Ramamoorthy, P., Dandawate, P., Jensen, R. A., & Anant, S. (2021). Celastrol and triptolide suppress stemness in triple negative breast cancer: Notch as a therapeutic target for stem cells. Biomedicines, 9(5), Article 482. https:\/\/doi.org\/10.3390\/BIOMEDICINES9050482","journal-title":"Biomedicines"},{"issue":"5","key":"10331_CR101","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22052518","volume":"22","author":"M Powers","year":"2021","unstructured":"Powers, M., Liu, L., Deemer, D., Chen, S., Scholl, A., Yoshinaga, M., & Liu, Z. (2021). Selenite inhibits Notch signaling in cells and mice. International Journal of Molecular Sciences, 22(5), Article 2518. https:\/\/doi.org\/10.3390\/IJMS22052518","journal-title":"International Journal of Molecular Sciences"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10331-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10331-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10331-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:28:39Z","timestamp":1774603719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10331-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":101,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10331"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10331-4","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"20"}}